You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康緣藥業(600557.SH):公司部分藥品納入《國家醫保目錄》
格隆匯 12-13 17:12

格隆匯12月13日丨康緣藥業(600557.SH)公佈,2023年12月13日,國家醫保局、人力資源社會保障部發布了《關於印發<國家基本醫療保險、工傷保險和生育保險藥品目錄(2023年)>的通知》(醫保發〔2023〕30號)。根據該通知,公司獨家品種散寒化濕顆粒、苓桂術甘顆粒通過談判首次納入《國家基本醫療保險、工傷保險和生育保險藥品目錄(2023年)》(以下簡稱《國家醫保目錄》);公司獨家品種銀杏二萜內酯葡胺注射液從《國家醫保目錄》協議期內談判藥品部分調整至中成藥部分,即納入常規目錄管理;公司獨家品種熱毒寧注射液在《國家醫保目錄》中成藥部分醫保支付範圍由“限二級及以上醫療機構重症患者”調整為“限二級及以上醫療機構”;公司獨家品種參烏益腎片通過簡易續約繼續納入《國家醫保目錄》協議期內談判藥品部分,醫保支付標準由1.3元(0.4g/片)調整為1.27元(0.4g/片);公司非獨家品種鹽酸格拉司瓊注射液、阿侖膦酸鈉片支付範圍解除限制;公司非獨家品種吸入用異丙託溴銨溶液於2023年獲批,為《國家醫保目錄》品種。除上述調整的產品外,公司其他納入《國家醫保目錄》(2023年)的產品與《國家醫保目錄》(2022年)保持不變。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account